These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 16373704

  • 1. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
    Albitar L, Laidler LL, Abdallah R, Leslie KK.
    Mol Cancer Ther; 2005 Dec; 4(12):1891-9. PubMed ID: 16373704
    [Abstract] [Full Text] [Related]

  • 2. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R.
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [Abstract] [Full Text] [Related]

  • 3. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R.
    Clin Cancer Res; 2004 Jan 15; 10(2):658-67. PubMed ID: 14760089
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
    Shien T, Doihara H, Hara H, Takahashi H, Yoshitomi S, Taira N, Ishibe Y, Teramoto J, Aoe M, Shimizu N.
    Breast Cancer; 2004 Jan 15; 11(4):367-73. PubMed ID: 15604992
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. EGFR isoforms and gene regulation in human endometrial cancer cells.
    Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, Leslie KK.
    Mol Cancer; 2010 Jun 25; 9():166. PubMed ID: 20579378
    [Abstract] [Full Text] [Related]

  • 8. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J.
    Clin Cancer Res; 2003 Apr 25; 9(4):1274-83. PubMed ID: 12684395
    [Abstract] [Full Text] [Related]

  • 9. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
    Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G.
    Br J Cancer; 2002 May 06; 86(9):1518-23. PubMed ID: 11986789
    [Abstract] [Full Text] [Related]

  • 10. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K.
    Oncol Rep; 2004 Nov 06; 12(5):1053-7. PubMed ID: 15492792
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 14. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M.
    Clin Cancer Res; 2004 Jan 15; 10(2):794-801. PubMed ID: 14760103
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K.
    Int J Cancer; 2002 Mar 10; 98(2):310-5. PubMed ID: 11857424
    [Abstract] [Full Text] [Related]

  • 16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 10; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 17. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
    Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ.
    Int J Cancer; 2001 Dec 15; 94(6):774-82. PubMed ID: 11745477
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
    Xu Y, Tong J, Ai Z, Wang J, Teng Y.
    J Obstet Gynaecol Res; 2012 Dec 15; 38(12):1358-66. PubMed ID: 22612393
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 20. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.